Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: A single-center experience

BMC Cancer

Volumn 5, Issue , 2005, Pages

  de Maio, Ermelinda ^a   Gravina, Adriano ^a   Pacilio, Carmen ^a   Amabile, Gerardo ^a   Labonia, Vincenzo ^a   Landi, Gabriella ^a   Nuzzo, Francesco ^a   Rossi, Emanuela ^a   D'Aiuto, Giuseppe ^a   Capasso, Immacolata ^a   Rinaldo, Massimo ^a   Morrica, Brunello ^a   Elmo, Massimo ^a   Di Maio, Massimo ^a   Perrone, Francesco ^a   de Matteis, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; AGE; AGED; ANEMIA; BLEEDING; BLOOD TOXICITY; BODY WEIGHT DISORDER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DYSURIA; ELDERLY CARE; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FISHER EXACT TEST; HEADACHE; HEARTBURN; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; RANK SUM TEST; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; SKIN TOXICITY; THORAX PAIN; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; HEMATOLOGIC DISEASE; MIDDLE AGED;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; METHOTREXATE; MIDDLE AGED; PATIENT COMPLIANCE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES;

EID: 26844432325     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-30     Document Type: Review

References (28)

1. Chu C, Tarone RE, Kessler LG: Recent trends in US breast cancer incidence, survival and mortality rates. J Natl Cancer Inst 1996, 88:1571-1579.
2. Surveillance, Epidemiology, and End Results (SEER) Program: Public use CDROM (1973-1995) Bethesda (MD): Cancer Statistics Branch, National Cancer Institute; 1998.
3. Early Breast Cancer Trialists' Collaborative Group: 2000 analysis overview results. 5th meeting of the EBCTCG Oxford, UK. September 21-22, 2000
4. Goldhirsch A, Glick GH, Gelber RD, Senn HJ: Meeting Highlights: Consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001, 19:3817-3827.
5. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer. J Natl Cancer Inst 2001, 93(13):979-989. November 1-3, 2000
6. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ: Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. J Clin Oncol 2003, 21:3357-3365.
7. Fargeot P, Bonneterre J, Rochè H, Lortholary A, Campone M, Van Praagh I, Monnier A, Namer M, Schraub S, Barats JC, Guastalla JP, Goudier MJ, Chapelle-Marcillac I: Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-Up Results of the French Adjuvant Study Group 08 Trial. J Clin Oncol 2004, 22:4674-4682.
8. Hutchins F, Unger JM, Crowley JJ: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 347(27):2061-67.
9. Kornblith AB, Kemeny M, Peterson BL, Wheeler J, Crawford J, Bartlett N, Fleming G, Graziano S, Muss H, Cohen HJ, for the Cancer and Leukemia Group B: Survey of Oncologists' Perceptions of Barriers to Accrual of Older Patients with Breast Carcinoma to Clinical Trials. Cancer 2002, 95:989-96.
10. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998, 16:2651-2658.
11. French Adjuvant Study Group: Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial. J Clin Oncol 2001, 19:602-611.
12. Nabholtz J-M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C, Weaver C, Walley B, Martin M, Chap L, Tomiak E, Juhos E, Guevin R, Howell A, Hainsworth J, Fornander T, Blitz S, Gazel S, Loret C, Riva A: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002, 21:36a. abstract 141
13. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L: Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21:1431-1439.
14. Biganzoli L, Goldhirsch A, Straehle C, Castiglione M, Therasse P, Aapro M, Minisini A, Piccart M: Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG). Ann Oncol 2004, 15:207-210.
15. Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thurlimann B, Price KN, Coates AS, Hurny C, Bernhard J, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Goldhirsch A, for the International Breast Cancer Study Group: Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients With Breast Cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 2000, 18:1412-1422.
16. Goldhirsch A, Glick JH, Gelber RD, Senn HJ: Meeting Highlights International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998, 90:1601-1608.
17. Extermann M, Balducci L, Lyman GH: What Threshold for Adjuvant Therapy in Older Breast Cancer Patients? J Clin Oncol 2000, 18:1709-1717.
18. Stiggelbout AM, de Haes JCJM: Patient Preference for Cancer Therapy: An Overview of Measurement Approaches. J Clin Oncol 2001, 19:220-230.
19. Duric V, Stockler M: Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile. Lancet Oncol 2001, 2:691-697.
20. Simes RJ, Coates AS: Patient Preferences for Adjuvant Chemotherapy of Early Breast Cancer: How Much Benefit Is Needed? J Natl Cancer Inst Monogr 2001, 30:146-152.
21. Extermann M, Albrand G, Chen H, Zanetta S, Schonwetter R, Zulian GB, Cantor A, Droz JP: Are Older French Patients As Willing As Older American Patients to Undertake Chemotherapy? J Clin Oncol 2003, 21:3214-3219.
22. De Michele A, Putt M, Zhang Y, Glick JH, Norman S: Older Age Predicts a Decline in Adjuvant Chemotherapy Recommendations for Patients with Breast Carcinoma. Evidence from a Tertiary Care Cohort of Chemotherapy-Eligible Patients. Cancer 2003, 97:2150-2159.
23. Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J, Edge S, Guadagnoli E, Lynch JJ, Meropol NJ, Weeks JC, Winn R, for the Outcomes and Preferences for Treatment in Older Women Nationwide Study (OPTIONS) Research Team: Patterns of Breast Carcinoma Treatment in Older Women. Patient Preference and Clinical and Physician Influences. Cancer 2000, 89:561-573.
24. Woodard S, Nadella PC, Kotur L, Wilson J, Burak WE, Shapiro CL: Older Women with Breast Carcinoma Are Less Likely to Receive Adjuvant Chemotherapy. Evidence of Possible Age Bias? Cancer 2003, 98:1141-1149.
25. Wyld L, Reed MW: The need for targeted research into breast cancer in the elderly. Br J Surg 2003, 90:388-399.
26. Colleoni M, Price KN, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A: Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate and fluorouracil. Lancet 1999, 354:130-131.
27. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schäfer P, Kurtz J, Sappino AP, Vlastos G: Undertreatment Strongly Decreases Prognosis of Breast Cancer in Elderly Women. J Clin Oncol 2003, 21:3580-3587.
28. Hainsworth JD, Burris HA 3rd, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA: Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001, 19:3500-3505.